ETTX Entasis Therapeutics Holdings Inc.

4.94
+0.03  (+1%)
Previous Close 4.91
Open 4.94
Price To Book 1.2
Market Cap 65,660,321
Shares 13,291,563
Volume 4,661
Short Ratio
Av. Daily Volume 11,685
Stock charts supplied by TradingView

NewsSee all news

  1. Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products,

  2. Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer

    WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant

  3. Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

    WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant

  4. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  5. GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

    Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections estimated each year;

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 data released June 13, 2019, supports further development.
ETX0282CPDP
Complicated urinary tract infections (cUTI)
Phase 3 top-line data due 2H 2020.
ETX2514SUL
Acinetobacter baumannii infections
Phase 3 data due 2021.
Zoliflodacin
Uncomplicated gonorrhea

Latest News

  1. Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update

    WALTHAM, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products,

  2. Entasis Therapeutics Appoints Dr. David Altarac as Chief Medical Officer

    WALTHAM, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant

  3. Entasis Therapeutics Announces Multiple Presentations at ID Week 2019

    WALTHAM, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company developing novel precision antibacterials to treat serious drug-resistant

  4. Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019

    WASHINGTON, Oct. 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven

  5. GARDP and Entasis Therapeutics Initiate Global Phase 3 Trial of Zoliflodacin, a First-in-Class Oral Antibiotic for the Treatment of Gonorrhea

    Randomized, open label trial will assess the efficacy and safety of zoliflodacin versus a combination of azithromycin and ceftriaxone, the current standard of care87 million new gonorrhea infections estimated each year;

  6. Entasis Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    WALTHAM, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products,